Endocrinology, Vol 137, 2739-2747, Copyright © 1996 by Endocrine Society

ARTICLES

Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells

RI Yarden, AH Lauber, D El-Ashry and SA Chrysogelos
Lombardi Cancer Center, Georgetown University, Washington, D.C. 20007, USA.

In breast cancer, epidermal growth factor (EGF) receptor (EGFR) expression is inversely correlated with expression of estrogen receptor (ER) and predicts the prognosis and failure of endocrine therapy. We report here, for the first time, that in ER-positive breast cancer cell lines, MCF-7, T47D, and BT474, 17 beta-estradiol (E2) transiently induced EGFR messenger RNA (mRNA) levels 2- to 3-fold; this induction was prevented by the presence of the antiestrogen ICI 164,384 and was also reflected in the level of EGFR protein. Up-regulation of EGFR mRNA is most likely due to a direct effect of ER on the EGFR gene, with no involvement of protein synthesis, as it was not inhibited in the presence of cycloheximide; however, the subsequent down-regulation of EGFR required de novo protein synthesis. E2 had no effect on EGFR mRNA stability, and EGFR transcript levels were found to parallel EGFR mRNA levels, further supporting a direct transcriptional mechanism in the regulation of EGFR expression by estrogens. Additionally, sequencing of the EGFR promoter revealed putative imperfect estrogen-responsive elements that were capable of binding human ER. The transient nature of EGFR induction by E2, with a rapid return to a basal level that is dependent on protein synthesis, suggests that breast cancer cells possess active mechanisms to maintain low levels of EGFR expression in the presence of estrogen and a functional ER.

This article has been cited by other articles:

				K. Britt, A. Ashworth, and M. Smalley Pregnancy and the risk of breast cancer Endocr. Relat. Cancer, December 1, 2007; 14(4): 907 - 933. [Abstract] [Full Text] [PDF]

				S. Banerjee, K. Sengupta, N. K. Saxena, K. Dhar, and S. K. Banerjee Epidermal Growth Factor Induces WISP-2/CCN5 Expression in Estrogen Receptor-{alpha}-Positive Breast Tumor Cells through Multiple Molecular Cross-talks Mol. Cancer Res., March 1, 2005; 3(3): 151 - 162. [Abstract] [Full Text] [PDF]

				G. Atalay, F. Cardoso, A. Awada, and M. J. Piccart Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer Ann. Onc., September 1, 2003; 14(9): 1346 - 1363. [Abstract] [Full Text] [PDF]

				A. T. Baron, E. M. Cora, J. M. Lafky, C. H. Boardman, M. C. Buenafe, A. Rademaker, D. Liu, D. A. Fishman, K. C. Podratz, and N. J. Maihle Soluble Epidermal Growth Factor Receptor (sEGFR/sErbB1) as a Potential Risk, Screening, and Diagnostic Serum Biomarker of Epithelial Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 103 - 113. [Abstract] [Full Text] [PDF]

				S. Tsutsui, A. Kataoka, S. Ohno, S. Murakami, J. Kinoshita, and Y. Hachitanda Prognostic and Predictive Value of Epidermal Growth Factor Receptor in Recurrent Breast Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3454 - 3460. [Abstract] [Full Text] [PDF]

				M. S. Cotroneo, J. Wang, W. A. Fritz, I.-E. Eltoum, and C. A. Lamartiniere Genistein action in the prepubertal mammary gland in a chemoprevention model Carcinogenesis, September 1, 2002; 23(9): 1467 - 1474. [Abstract] [Full Text] [PDF]

				C. I. Spiridon, M.-A. Ghetie, J. Uhr, R. Marches, J.-L. Li, G.-L. Shen, and E. S. Vitetta Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity of a Human Breast Cancer Cell Line in Vitro and in Vivo Clin. Cancer Res., June 1, 2002; 8(6): 1720 - 1730. [Abstract] [Full Text] [PDF]

				E. J. Filardo, J. A. Quinn, A. R. Frackelton Jr., and K. I. Bland Estrogen Action Via the G Protein-Coupled Receptor, GPR30: Stimulation of Adenylyl Cyclase and cAMP-Mediated Attenuation of the Epidermal Growth Factor Receptor-to-MAPK Signaling Axis Mol. Endocrinol., January 1, 2002; 16(1): 70 - 84. [Abstract] [Full Text] [PDF]

				N. Kirma, K. Gill, U. Mandava, and R. R. Tekmal Overexpression of Aromatase Leads to Hyperplasia and Changes in the Expression of Genes Involved in Apoptosis, Cell Cycle, Growth, and Tumor Suppressor Functions in the Mammary Glands of Transgenic Mice Cancer Res., March 1, 2001; 61(5): 1910 - 1918. [Abstract] [Full Text]

				R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]

				L. Salvatori, L. Ravenna, M. P. Felli, M. R. Cardillo, M. A. Russo, L. Frati, A. Gulino, and E. Petrangeli Identification of an Estrogen-Mediated Deoxyribonucleic Acid-Binding Independent Transactivation Pathway on the Epidermal Growth Factor Receptor Gene Promoter Endocrinology, June 1, 2000; 141(6): 2266 - 2274. [Abstract] [Full Text] [PDF]

				S. Al-Haddad, Z. Zhang, E. Leygue, L. Snell, A. Huang, Y. Niu, T. Hiller-Hitchcock, K. Hole, L. C. Murphy, and P. H. Watson Psoriasin (S100A7) Expression and Invasive Breast Cancer Am. J. Pathol., December 1, 1999; 155(6): 2057 - 2066. [Abstract] [Full Text] [PDF]

				W. G.R. Angus, M. C. Larsen, and C. R. Jefcoate Expression of CYP1A1 and CYP1B1 depends on cell-specific factors in human breast cancer cell lines: role of estrogen receptor status Carcinogenesis, June 1, 1999; 20(6): 947 - 955. [Abstract] [Full Text] [PDF]

				K. Szepeshazi, A. V. Schally, G. Halmos, N. Lamharzi, K. Groot, and J. E. Horvath A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers PNAS, September 30, 1997; 94(20): 10913 - 10918. [Abstract] [Full Text] [PDF]